MRCPsychLog in
Back to topics

Read this topic

Clinical Psychopharmacology · Paper A

Aripiprazole partial D2 agonism

The idea

Aripiprazole is a 'dopamine stabiliser' rather than a dopamine blocker — a partial D2/D3 agonist whose small, fixed dopamine signal calms an overactive psychotic pathway down while leaving movement and prolactin pathways largely switched on. The same molecule can look like an antagonistA drug that blocks a receptor, stopping it from being activated.Read more → in one dopamine circuit and like a weak agonistA drug or chemical that activates a receptor to produce an effect.Read more → in another, purely because of how much dopamine was already competing for the receptor before it arrived.

How it works

  • Aripiprazole is a partial agonistA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more → at D2 and D3 dopamine receptors (intrinsic activity roughly 0.3, versus 1 for dopamine itself and 0 for a full antagonistA drug that blocks a receptor, stopping it from being activated.Read more → like haloperidol), plus a partial agonist at serotonin 5-HT1AA serotonin receptor subtype whose partial activation is linked to reducing anxiety.Read more → and an antagonist at 5-HT2AA serotonin receptor subtype that many antipsychotic drugs block, thought to help their antidepressant and antipsychotic effect.Read more → — the same 5-HT2A-blocking action shared by every 'atypical' antipsychotic.
  • Because the signal is only PARTIAL, its net effect flips direction with local dopamine tone. In the dopamine-overactive mesolimbic pathwayA dopamine brain pathway linked to reward and motivation, and to the positive symptoms of psychosis.Read more → (driving positive psychotic symptoms) it behaves like a weak antagonistA drug that blocks a receptor, stopping it from being activated.Read more →, lowering net activity; in the dopamine-normal nigrostriatal and tuberoinfundibular pathwaysA dopamine brain pathway that normally restrains prolactin release, whose blockade by antipsychotics raises prolactin.Read more → it behaves like a weak agonistA drug or chemical that activates a receptor to produce an effect.Read more →, keeping enough activity going to spare movement and prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → regulation.
  • This dual-direction behaviour is why it is called a dopamine stabiliser rather than simply a D2 blocker — mechanistically distinct from every full-antagonistA drug that blocks a receptor, stopping it from being activated.Read more → drug grouped alongside it under the 'atypical antipsychotic' label.
  • Clinically this produces a recognisable trade: LOW risk of prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → elevation (sometimes added specifically to bring another antipsychotic's raised prolactin back down), LOW extrapyramidal risk and LOW metabolic burden compared with olanzapine or clozapine. That trade comes at the cost of a comparatively HIGH risk of akathisiaAn inner restlessness and urge to keep moving, a common side effect of antipsychotic drugs.Read more →, restlessness and insomnia, because the partial agonism itself still provides some dopaminergicRelating to dopamine, a brain chemical involved in reward, motivation and movement.Read more → drive rather than none.
  • It is licensed for schizophreniaA long-term mental illness involving episodes of psychosis such as hallucinations and delusions.Read more →, acute maniaA period of abnormally elevated mood, energy and activity, seen in bipolar disorder.Read more → and bipolar maintenance, as an augmentationAdding a second drug to boost the effect of a treatment that has only partly worked on its own.Read more → agent in treatment-resistant depression, and for irritability associated with autism — all trading on the same low-prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more →, low-metabolic-burden, activating profile.
  • Two related partial agonistsA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more → share the class but not the exact profile: brexpiprazole has lower intrinsic dopamine activity than aripiprazole (less activating, more sedating/weight gain), and cariprazine is D3-preferring with a very long-acting active metaboliteA breakdown product of a drug that is itself still able to produce an effect in the body.Read more →.

How to spot it

  • A vignette describing a patient whose prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → level FALLS or normalises after switching antipsychotics, while they develop NEW restlessness or an urge to keep moving, is describing aripiprazole's partial-agonistA drug or chemical that activates a receptor to produce an effect.Read more → signature — falling prolactin plus rising activation is close to a fingerprint for this mechanism.
  • A vignette describing a drug with aripiprazole's exact three-receptor profile (D2/D3 partial agonistA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more →, 5-HT1AA serotonin receptor subtype whose partial activation is linked to reducing anxiety.Read more → partial agonist, 5-HT2AA serotonin receptor subtype that many antipsychotic drugs block, thought to help their antidepressant and antipsychotic effect.Read more → antagonistA drug that blocks a receptor, stopping it from being activated.Read more →) but LESS activation and MORE sedation/weight gain is describing brexpiprazole, not aripiprazole.
  • A vignette describing effects or side effects that persist for WEEKS after stopping a dopamine partial agonistA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more → is describing cariprazine's long-acting active metaboliteA breakdown product of a drug that is itself still able to produce an effect in the body.Read more →, not aripiprazole's standard pharmacokinetics.
  • A vignette describing negative-symptom benefit alongside a RISING prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → level and no serotonin receptor involvement is describing amisulpride, a full antagonistA drug that blocks a receptor, stopping it from being activated.Read more →, not a partial agonistA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more →.
  • A vignette describing psychosis treatment in Parkinson's disease specifically chosen to avoid worsening motor symptoms is describing pimavanserin, which has no dopamine receptor activity at all — not aripiprazole, which still has some.
  • A vignette describing mandatory weekly blood monitoring alongside low

Tell it apart

  • Aripiprazole (partial D2/D3 agonistA drug or chemical that activates a receptor to produce an effect.Read more →) vs haloperidol/risperidone/olanzapine/amisulpride (full D2 antagonistsA drug that blocks a receptor, stopping it from being activated.Read more →) — a full antagonist blocks the tuberoinfundibular pathwayA dopamine brain pathway that normally restrains prolactin release, whose blockade by antipsychotics raises prolactin.Read more → completely, raising prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more →; aripiprazole's partial signal spares it, so prolactin stays low or falls.
  • Aripiprazole vs brexpiprazole — both D2/D3 partial agonistsA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more → with the same three-receptor profile, but brexpiprazole has LOWER intrinsic dopamine activity: less akathisiaAn inner restlessness and urge to keep moving, a common side effect of antipsychotic drugs.Read more →/activation, more sedation and weight gain.
  • Aripiprazole vs cariprazine — both partial agonistsA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more →, but cariprazine is D3-PREFERRING rather than balanced D2/D3, and its active metaboliteA breakdown product of a drug that is itself still able to produce an effect in the body.Read more → persists for weeks, unlike aripiprazole's standard once-daily dosing.
  • Aripiprazole vs olanzapine — both show low EPSExtrapyramidal side effects, movement problems caused by drugs that block dopamine.Read more → and low prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more →, but for different reasons: aripiprazole via partial agonism, olanzapine via full antagonism plus strong H1/M1 blockade that instead drives a high metabolic burden aripiprazole does not share.
  • Aripiprazole vs clozapine — both show low prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → elevation, but clozapine reaches this through weak D2 antagonism (not partial agonism) and is reserved for treatment resistance with mandatory FBCFull blood count, a blood test that measures red cells, white cells and platelets.Read more →

Watch for

  • ⚠️ Assuming any antipsychotic with low prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → elevation and low EPSExtrapyramidal side effects, movement problems caused by drugs that block dopamine.Read more → must share aripiprazole's partial-agonistA drug or chemical that activates a receptor to produce an effect.Read more → mechanism — olanzapine and quetiapine reach a similar clinical picture through full antagonism (strong H1/M1 blockade, or fast receptor dissociationA disconnection between a person's thoughts, feelings, memories, or sense of identity, often as a response to stress.Read more →) instead.
  • Confusing aripiprazole with brexpiprazole or cariprazine just because all three are 'dopamine partial agonistsA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more →' — the specific detail (activation vs sedation, D2/D3 balance vs D3-preference, standard vs weeks-long half-lifeThe time it takes for the amount of a drug in the body to fall by half.Read more →) is what actually distinguishes them in a vignette.
  • Treating new restlessness or agitation on aripiprazole as worsening psychosis or anxiety rather than screening for akathisiaAn inner restlessness and urge to keep moving, a common side effect of antipsychotic drugs.Read more →, its most characteristic and most under-recognised side effect.
  • Assuming amisulpride's usefulness for negative symptoms means it shares aripiprazole's mechanism — amisulpride is a full antagonistA drug that blocks a receptor, stopping it from being activated.Read more → and reliably raises prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more →, unlike aripiprazole.
  • Reaching for standard anticholinergicBlocking the action of acetylcholine, a nerve chemical, causing effects like a dry mouth and blurred vision.Read more → treatment when aripiprazole causes akathisiaAn inner restlessness and urge to keep moving, a common side effect of antipsychotic drugs.Read more → — because the akathisia is dopamine-mediated rather than caused by dopamine excess, dose reduction or a beta-blocker (propranolol) is the first-line approach instead.
  • Forgetting that a comparatively low metabolic burden does not mean NO metabolic risk — routine metabolic monitoring still applies to aripiprazole.

Use it again

  • First ask, does the stem describe a drug blocking dopamine completely (full antagonistA drug that blocks a receptor, stopping it from being activated.Read more →), partially (partial agonistA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more →), or not at all (pure serotonergicRelating to serotonin, a brain chemical involved in mood.Read more → agent)? That single question routes almost every question in this family.
  • If a partial agonistA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more → is described, check the specific detail given — activation vs sedation, balanced D2/D3 vs D3-preference, standard vs weeks-long duration of effect — before naming aripiprazole, brexpiprazole or cariprazine; do not default to aripiprazole just because it is the most familiar name.
  • If prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → is FALLING or staying normal on a newly started drug, favour a partial agonistA drug that activates a receptor but produces a smaller effect than a full agonist, even at a high dose.Read more → (aripiprazole) or a weak antagonistA drug that blocks a receptor, stopping it from being activated.Read more → (clozapine) over a full antagonist; if prolactin is RISING, favour a full antagonist even if the drug is also useful for negative symptoms (amisulpride).
  • If the clinical context is Parkinson's disease psychosis specifically, favour a drug with NO dopamine activity at all (pimavanserin) over aripiprazole, which still carries some dopaminergicRelating to dopamine, a brain chemical involved in reward, motivation and movement.Read more → risk.
  • If new restlessness appears on an antipsychotic with an otherwise low side-effect burden, check for akathisiaAn inner restlessness and urge to keep moving, a common side effect of antipsychotic drugs.Read more → before assuming anxiety or relapse, and reach for dose reduction or a beta-blocker rather than an anticholinergicBlocking the action of acetylcholine, a nerve chemical, causing effects like a dry mouth and blurred vision.Read more →.

In detail

In this lesson

  1. Hook — a drug that calms and activates at once
  2. Plain definition
  3. The critical caveat — one drug, two opposite jobs
  4. First principles — why partial agonism produces this pattern
  5. Structured walk-through — following the effect through the brain's dopamine pathways
  6. Look-alikes and differentials
  7. Diagnosis — how the profile is actually recognised
  8. Management — what is actually done, and whose guidance it rests on
  9. Exam pearl
  10. In one line

In this lesson

  1. Hook — a drug that calms and activates at once
  2. Plain definition
  3. The critical caveat — one drug, two opposite jobs
  4. First principles — why partial agonism produces this pattern
  5. Structured walk-through — following the effect through the brain's dopamine pathways
  6. Look-alikes and differentials
  7. Diagnosis — how the profile is actually recognised
  8. Management — what is actually done, and whose guidance it rests on
  9. Exam pearl
  10. In one line

Hook — a drug that calms and activates at once

Imagine two patients started on the same antipsychotic. One had wild, racing psychotic thoughts that settle down within weeks. Another, previously flat and withdrawn, becomes noticeably more alert and talkative — sometimes restless, unable to sit still. Same tablet, same dose, opposite-looking change. Most antipsychotics either turn dopamine signalling down everywhere or leave it alone; this one somehow pushes it toward the middle no matter which direction it started from. That drug is aripiprazole, and understanding how one molecule can do both is the key to everything else on this page.

Plain definition

Aripiprazole is an antipsychotic medicine that works as a (a drug that only partly switches a receptor on, instead of fully turning it on like the body's own chemical would, or fully blocking it like most other antipsychotics do) at the brain's D2 dopamine receptor (the docking site dopamine binds to, which most antipsychotics work by blocking). Where a typical antipsychotic such as haloperidol is a full (it blocks the receptor completely, however much dopamine is around), aripiprazole sits in the receptor and delivers a smaller, steady signal — enough to calm an overactive dopamine pathway down, but enough to keep an underactive one ticking over. Because of this, it is often called a dopamine stabiliser rather than simply a blocker.

The critical caveat — one drug, two opposite jobs

Here is the point almost everyone gets backwards at first: aripiprazole does not simply 'reduce dopamine'. In the mesolimbic pathway (the dopamine circuit running through the , over-active in psychosis and responsible for positive symptoms such as and ), dopamine levels are already too high, so aripiprazole's smaller partial signal acts functionally like an — net dopamine activity falls, and psychosis eases. In the nigrostriatal and (circuits controlling movement and release), dopamine tone is normal or even needed, so the same drug's partial signal acts functionally like a weak — enough activity keeps going that movement and hormone regulation are not switched off the way they are by a full blocker. One receptor, one drug, two directions of effect, depending on how much dopamine was there to begin with.

First principles — why partial agonism produces this pattern

Every drug that acts on a receptor has intrinsic activity (how strongly it switches the receptor on once bound, scored from 0 for a pure to 1 for the body's own full ). Dopamine itself has intrinsic activity of 1. A full antagonist like haloperidol has intrinsic activity of 0 — it occupies the receptor and produces nothing, and because it physically sits in the site, it also stops nearby dopamine from getting in at all. Aripiprazole sits in between, at roughly 0.3.

Suppose a pathway is flooded with dopamine, each molecule pushing the receptor hard toward fully on. Aripiprazole competes for the same docking site and, molecule for molecule, delivers a smaller signal — so swapping dopamine for aripiprazole turns that pathway's average activity DOWN. Now suppose a different pathway has very little dopamine around. Aripiprazole still delivers its fixed 0.3 signal regardless, so in a nearly-empty pathway it actually turns activity UP compared with having almost nothing there at all. The molecule, the receptor and the intrinsic activity never change — only the direction of the net effect changes, and that depends entirely on how much dopamine was competing for the receptor before the drug arrived.

Structured walk-through — following the effect through the brain's dopamine pathways

Picture four dopamine pathways side by side, each usually taught separately. In the , dopamine runs high in psychosis; aripiprazole's partial block brings it back toward a normal middle range, and and improve. In the mesocortical pathway, dopamine is often already low (thought to underlie negative and cognitive symptoms of ); aripiprazole's partial agonism can nudge activity up rather than down, part of why it is sometimes chosen when negative symptoms are prominent.

In the , which controls smooth voluntary movement, dopamine tone is normally healthy; because aripiprazole never switches this pathway off completely the way a full does, extrapyramidal side effects (movement disorders such as parkinsonism and ) are comparatively uncommon. In the , which normally keeps release suppressed via dopamine, the same partial signal is usually enough to keep prolactin suppressed — so aripiprazole rarely raises it, and can even be added to another antipsychotic specifically to bring an already-elevated prolactin level back down.

Aripiprazole also acts, more modestly, at two other receptors: it is a at the serotonin receptor (thought to add to its antipsychotic and -type effects) and an at (the serotonin-blocking action shared by every 'atypical' antipsychotic, contributing to a lower risk of movement side effects than older drugs).

Look-alikes and differentials

Several other antipsychotics are easy to confuse with aripiprazole, and the table below separates them by mechanism rather than by brand familiarity.

DrugHow it differs from aripiprazole
Haloperidol, risperidone, olanzapineFull D2 — block the receptor completely, raising and (haloperidol especially) causing more extrapyramidal side effects.
BrexpiprazoleSame D2/D3 family, but lower intrinsic activity — less activating, more sedating and more weight gain.
CariprazineAlso a partial agonist, but D3-preferring, with a long-acting that lingers for weeks.
AmisulprideA full D2/D3 antagonist with no serotonin activity — reliably raises prolactin despite helping negative symptoms.
PimavanserinEssentially no dopamine receptor activity — works purely through , hence its use in Parkinson's disease psychosis.

Diagnosis — how the profile is actually recognised

There is no laboratory test that 'diagnoses' a ; you recognise this pharmacological pattern from a patient's clinical picture and monitoring results, not from a single investigation. A level (a blood test) that stays normal or falls after starting aripiprazole — sometimes used deliberately as an add-on when another antipsychotic has caused galactorrhoea or amenorrhoea — is a strong pharmacological signature. Screening for (using a structured rating scale) rather than assuming any new restlessness is anxiety or worsening psychosis is essential, because akathisia is aripiprazole's most characteristic and most under-recognised side effect. Routine metabolic monitoring (weight, waist circumference, fasting glucose and lipids) still applies, since even a comparatively metabolically-friendly drug is not risk-free.

Management — what is actually done, and whose guidance it rests on

NICE guidance (CG178, Psychosis and in adults) frames antipsychotic choice as a shared decision between prescriber and patient, made on side-effect profile as much as efficacy, since head-to-head efficacy between antipsychotics is broadly similar — this is exactly where aripiprazole's distinct profile (low elevation, comparatively low metabolic burden, comparatively higher activation/ risk) becomes clinically relevant rather than academic. First-line management of aripiprazole-induced akathisia is dose reduction or, if that fails, adding a beta-blocker such as propranolol; because the akathisia is dopamine-mediated rather than caused by dopamine excess, the treatment used for -induced movement disorders is less reliably effective here. Aripiprazole is also used as an strategy — added at low dose to another antipsychotic, or to an antidepressant in treatment-resistant depression — specifically to exploit its prolactin-normalising, comparatively weight-neutral profile rather than to add a second full blocker.

Exam pearl

Whenever a vignette describes a patient switched to a new antipsychotic whose level then falls or normalises, while they develop new restlessness or difficulty sitting still, think aripiprazole before you think of any full D2 — the combination of falling prolactin and rising activation is close to a fingerprint for partial agonism. Before you move on: could you explain to a friend why the same drug, at the same dose, can turn one dopamine pathway down and another up?

In one line

Aripiprazole is a D2/D3 — a dopamine stabiliser that lowers overactive dopamine signalling in psychosis while leaving movement and pathways largely alone, trading a low risk of prolactin rise and metabolic harm for a comparatively higher risk of .

Try a question from this area

  • Question 1
  • Question 2
  • Question 3
prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more →
elevation is describing clozapine, reached through weak antagonism, not aripiprazole's partial agonism.
monitoring that aripiprazole never requires.
  • Aripiprazole vs amisulpride — both are used for negative symptoms, but amisulpride is a pure D2/D3 full antagonistA drug that blocks a receptor, stopping it from being activated.Read more → with no serotonin activity at all, and reliably raises prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → because it never partially spares the tuberoinfundibular pathwayA dopamine brain pathway that normally restrains prolactin release, whose blockade by antipsychotics raises prolactin.Read more →.
  • Aripiprazole vs pimavanserin — both show a low extrapyramidal burden, but pimavanserin has NO dopamine receptor activity whatsoever (pure 5-HT2AA serotonin receptor subtype that many antipsychotic drugs block, thought to help their antidepressant and antipsychotic effect.Read more →), which is why it is chosen specifically for Parkinson's disease psychosis.